Literature DB >> 10952022

Elevated A beta and apolipoprotein E in A betaPP transgenic mice and its relationship to amyloid accumulation in Alzheimer's disease.

Y M Kuo1, F Crawford, M Mullan, T A Kokjohn, M R Emmerling, R O Weller, A E Roher.   

Abstract

BACKGROUND: Amyloid-beta (A beta) accumulates in plaques and as cerebral amyloid angiopathy (CAA) in the brains of both Alzheimer's disease (AD) patients and transgenic A betaPPswe/tg2576 (tg2576) mice. Increasingly, evidence in humans and mice shows this process to be modulated by apolipoprotein E (apoE).
MATERIALS AND METHODS: To explore this relationship, we measured apoE and A beta levels in brains of tg2576 mice and controls at intervals between 2 and 20 months. In addition, A beta concentrations in plasma and muscle of these animals were also quantified.
RESULTS: Quite strikingly, we found that the amount of tg2576 mice brain apoE was elevated by an average of 45%, relative to the control mice from 2 months on. The level of brain apoE soared after 14 months to almost 60% greater than the level found in control mice. A beta concentrations in brains before 9 months were less than 2 ng/mg of protein, but by 14 months concentrations rose to 8.7 ng/mg, and by 20 months to 47 ng/mg. In plasma, we noted that the levels of A beta in tg2576 mice declined from above 30 ng/ml prior to 12 months to 14 ng/ml by 14 months. Histology showed that A beta plaques and CAA began to be discernible in the tg2576 mice at about 9 and 20 months of age, respectively.
CONCLUSIONS: ApoE was immunocytochemically detected in neuritic plaques that were positive for thioflavine-S. We suggest that the elevation of brain apoE in tg2576 mice participates in an age-related dysregulation of A beta clearance and signals the start of A beta sequestration during the time of cognitive dysfunction.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10952022      PMCID: PMC1949958     

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  20 in total

Review 1.  Disorder-to-order conformational transitions in protein structure and its relationship to disease.

Authors:  Paola Mendoza-Espinosa; Victor García-González; Abel Moreno; Rolando Castillo; Jaime Mas-Oliva
Journal:  Mol Cell Biochem       Date:  2009-04-09       Impact factor: 3.396

Review 2.  Amyloid precursor protein transgenic mouse models and Alzheimer's disease: understanding the paradigms, limitations, and contributions.

Authors:  Tyler A Kokjohn; Alex E Roher
Journal:  Alzheimers Dement       Date:  2009-07       Impact factor: 21.566

3.  Apolipoprotein (apo) E4 enhances amyloid beta peptide production in cultured neuronal cells: apoE structure as a potential therapeutic target.

Authors:  Shiming Ye; Yadong Huang; Karin Müllendorff; Liming Dong; Gretchen Giedt; Elaine C Meng; Fred E Cohen; Irwin D Kuntz; Karl H Weisgraber; Robert W Mahley
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-12       Impact factor: 11.205

4.  Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis.

Authors:  R Lyle Patton; Walter M Kalback; Chera L Esh; Tyler A Kokjohn; Gregory D Van Vickle; Dean C Luehrs; Yu-Min Kuo; John Lopez; Daniel Brune; Isidro Ferrer; Eliezer Masliah; Amanda J Newel; Thomas G Beach; Eduardo M Castaño; Alex E Roher
Journal:  Am J Pathol       Date:  2006-09       Impact factor: 4.307

5.  Amyloid Accumulation Drives Proteome-wide Alterations in Mouse Models of Alzheimer's Disease-like Pathology.

Authors:  Jeffrey N Savas; Yi-Zhi Wang; Laura A DeNardo; Salvador Martinez-Bartolome; Daniel B McClatchy; Timothy J Hark; Natalie F Shanks; Kira A Cozzolino; Mathieu Lavallée-Adam; Samuel N Smukowski; Sung Kyu Park; Jeffery W Kelly; Edward H Koo; Terunaga Nakagawa; Eliezer Masliah; Anirvan Ghosh; John R Yates
Journal:  Cell Rep       Date:  2017-11-28       Impact factor: 9.423

Review 6.  APP transgenic mice: their use and limitations.

Authors:  Claudia Balducci; Gianluigi Forloni
Journal:  Neuromolecular Med       Date:  2010-12-09       Impact factor: 3.843

Review 7.  The pathogenic implication of abnormal interaction between apolipoprotein E isoforms, amyloid-beta peptides, and sulfatides in Alzheimer's disease.

Authors:  Xianlin Han
Journal:  Mol Neurobiol       Date:  2010-01-07       Impact factor: 5.590

8.  Apolipoprotein E mediates sulfatide depletion in animal models of Alzheimer's disease.

Authors:  Hua Cheng; Yunhua Zhou; David M Holtzman; Xianlin Han
Journal:  Neurobiol Aging       Date:  2008-08-31       Impact factor: 4.673

9.  Serum Abeta levels as predictors of conversion to mild cognitive impairment/Alzheimer disease in an ADAPT subcohort.

Authors:  Laila Abdullah; Cheryl Luis; Daniel Paris; Benoit Mouzon; Ghania Ait-Ghezala; Andrew P Keegan; Duolao Wang; Fiona Crawford; Michael Mullan
Journal:  Mol Med       Date:  2009-08-18       Impact factor: 6.354

10.  Cerebral amyloid angiopathy in the aetiology and immunotherapy of Alzheimer disease.

Authors:  Roy O Weller; Stephen D Preston; Malavika Subash; Roxana O Carare
Journal:  Alzheimers Res Ther       Date:  2009-10-12       Impact factor: 6.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.